I followed you in that one. Also gambling on AAPL APR 20 $440 calls and have been holding LCC MAR 16 $14 Calls for about almost a week. Can't remember the last time I held anything that long, lol!
09:01 ABIO ARCA biopharma announces a 6-for-1 reverse split of its common stock (0.45 ) Co announced a 6-for-1 reverse split of its common stock. The reverse stock split became effective on March 4, 2013 at 5:01 p.m. Eastern Time, and ARCA's common stock will continue trading on The NASDAQ Capital Market, on a split-adjusted basis, when the market opens on Tuesday, March 5, 2013.
09:01 PGNX Progenics Pharm's Novel Small Molecule Drugs Targeting PSMA successfully visualize prostate cancer; positive data reported in The Journal of Nuclear Medicine (2.84 ) Co reported positive clinical data from a study of two novel radiolabeled small molecules targeting prostate-specific membrane antigen (PSMA). The imaging agents -- 123I-MIP-1072 and 123I-MIP-1095 -- had a high sensitivity of lesion detection in bone, tissue and the prostate gland with minimal retention in non-target tissue. Separate phase 1 studies were conducted under an exploratory investigational new drug (IND) application to measure the potential effectiveness of the small molecules in diagnosing and staging prostate cancer. In the first study, seven patients with documented prostate cancer were administered doses of 123I-MIP-1072 and 123I-MIP-1095, two weeks apart. In the second study, six healthy volunteers received 123I-MIP-1072 only. Whole body planar imaging and single photon emission computed tomography (SPECT)/computed tomography (CT) were performed for each group, and pharmacokinetics, tissue distribution, excretion, safety and organ radiation dose were analyzed. Based on the data reported, Progenics is conductinga global, multi-center phase 2 trial investigating a next generation radiolabeled small molecule targeting PSMA, MIP-1404.
08:35 SQNM Sequenom: Incrementally more positive ahead of earnings following management meeting - Maxim (4.55 ) Maxim recommends that investors Buy shares of SQNM following its recent meeting with management. The company's upcoming earnings release should be a positive catalyst for shares, driven by an update to the company's MaterniT21 run rate, covered lives, and 1Q13 salesforce expansion. Although firm believes that competition is taking share of the NIPT market, SQNM reports that it is not yet seeing an impact from recently announced partnerships, and it remains confident in its forecast that the company captures more than a third of the total market within two to four years.
08:20 NWBO Northwest Biotherapeutics reports DCVax-Direct Phase I/II trial for all inoperable solid tumors is expected to produce ongoing results in 2013; endpoint of tumor regression could be seen within months (3.48 ) Co announced today that its Phase I/II DCVax-Direct clinical trial for all inoperable solid tumor cancers is planned to begin within approximately the next sixty days. As a Phase I/II trial, this trial is not blinded and the results will be seen as the trial proceeds. With an efficacy endpoint of tumor regression (i.e., tumor shrinkage or elimination), this innovative trial is expected to yield meaningful ongoing results by the second half of 2013.
8:19 SUMRX Gapping up/down: CREE +3.3% on guidance, CPWR +5.6%, financial and Metals/mining stocks trading higher... SHFL -4.6% on earnings, JCP -3.5% Gapping up: In reaction to strong earnings/guidance: APP +16.3%, ASNA +16.2%, SNTS +12.3%, PKOH +7.8%, CREE +3.3%, NLS +1.8% (light volume).
M&A related: CPWR +5.6% (Compuware receiving buyout interest from private equity; price not discussed, according to reports), GDI +0.5% (KKR close to buying Gardner Denver, according to reports).
Select financial related names showing strength: IRE +3.9%, ING +2.3%, CS +1.4%, DB +1.4% (also upgrade at Exane), HBC +0.5% (Regulators have given HBC the OK to increase dividend, according to reports).
Select oil/gas related names showing strength: RIG +1.9%, SDRL +1.6% (upgraded to Overweight from Neutral at HSBC Securities), RDS.A +1.2%, TOT +0.6%, BP +0.4%.
Other news: HIMX +15.7% (hearing move attributed to patent news ), ACRX +10.4% (Top-line data show primary endpoint achieved in pivotal phase 3 study of Sufentanil NanoTab PCA system for post-operative pain in major open abdominal surgery patients), ZOLT +5.4% (Quinpario Partners discloses group ownership of 10.13% in Zoltek), PERI +4.9% (still checking), QCOM +2.8% (increases quarterly dividend by 40% to $0.35 per share from $0.25 per share; announces new $5 bln stock repurchase program ), GILD +2.6% (AHF demands FDA reversal on use of Gilead's HIV prevention pill for women), GNW +2.3% (continued strength),SHLD +1.8% (attributed to Eddie Lampert transactions), NOK +1.7% and BBRY +0.7% (still checking for anything specific), VNO +1% (reports VNO selling the JCP shares).
Analyst comments: ANTH +13.8% (thinly traded, initiated with a Buy at Jefferies), MTG +7.7% and RDN +2.3% (upgraded at Barclays), YHOO +0.7% ( upgraded to Buy at Cantor Fitzgerald), GMCR +0.6% (Hearing positive comments at Lazard; reiterates Buy rating and $58 tgt), GOOG +0.6% (tgt to $1000 from $875 at Jefferies)
Gapping down: In reaction to disappointing earnings/guidance/SSS: SHFL -4.6%, REGI -3.4%, WAG -0.4%, (light volume).
Other news: IPXL -16.5% (provides an update on FDA inspection of Hayward Facility: FDA issued a new Form 483 with 12 observations ), TRLA -5.4% (files $100 mln common stock offering in S-1 filing), CWH -4.2% ( announces that motions for temporary restraining orders to block equity offering closing have been denied), HSP -4.1% (discloses FDA inspection update; FDA issued a Form 483 with 20 observations), JCP -3.5% (J. C. Penney follow up: Deutsche Bank offering 10 mln share block of J.C. Penny stock between $16.40-16.60 per share, according to reports), WPZ -3.3% (announces public offering and concurrent private placement of common units), HGR -3.3% (to delay filing of 10-K), JAZZ -2.2% (announces public offering of 5.375 mln ordinary shares by selling shareholders), FR -2.1% ( announces public offering of 8.4 mln shares of its common stock), MBI -1.8% (modestly pulling back).
Market Data 
Markets 
AI
